Medyria
Swiss medtech company that engineers technologies for endovascular catheter navigation and sensing.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
* | CHF1.5m | Growth Equity VC | |
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1 % | (8 %) | 4 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Medyria specializes in developing advanced medical devices that guide blood flow velocity to improve the safety and effectiveness of cardiovascular procedures. The company's primary clients are cardiovascular surgeons who perform endovascular procedures, which are minimally invasive surgeries conducted within blood vessels. Medyria operates in the medical technology market, focusing on innovations that reduce procedural risks and complications. The business model revolves around the sale of its proprietary devices, such as the TrackCath Catheter, which is designed to minimize X-ray exposure and contrast media usage, thereby reducing overall costs and enhancing patient and physician safety. Revenue is generated through the direct sale of these devices to hospitals and medical institutions, as well as through partnerships and collaborations with healthcare providers.
Keywords: cardiovascular, endovascular, blood flow, medical devices, TrackCath Catheter, patient safety, physician safety, procedural efficiency, X-ray reduction, contrast media.